Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma - Clinical Genitourinary Cancer
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
JCM | Free Full-Text | Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Overall survival in leiomyosarcoma patients. | Download Scientific Diagram
Hopes and failures in front-line ovarian cancer therapy - ScienceDirect
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma | NEJM
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials - The Lancet Oncology
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort - Mustafa Karaağaç, Yasin Sezgin, Melek Karakurt Eryılmaz, Murat Araz, Muhammet Ali
Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma | Cell Death Discovery
Biomedicines | Free Full-Text | Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
Overall Survival and Progression-free Survival among IMDC... | Download Scientific Diagram
Frontiers | Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
Full article: Pazopanib for the treatment of soft-tissue sarcoma
![PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/343485ee055845a60e57da69b711a4ea3bb2d505/4-Figure2-1.png "PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar")
PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar
Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review - Chen - Translational Cancer Research
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | NEJM
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
Overall survival for first-line IO combination therapies. CI =... | Download Scientific Diagram
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Votrient 400 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc)
ASCO 2019: Randomized, Double-Blind Phase III Study of Pazopanib versus Placebo in Patients with Metastatic Renal Cell Carcinoma who have no Evidence of Disease Following Metastasectomy - Medical Oncologist Perspective
